Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| GlaxoSmithKline | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to estimate a direct/indirect medical cost and to provide evidence establishing efficient strategies to reduce medical costs of COPD in Korea.
This study is a multi-center research on economic burdens of COPD for a year. It is composed of three phases detailed as follow.
Phase 1: Direct Cost Estimation in COPD patients (N = 400) Direct cost determined as amount of money expended to medical institutes for treatment. Estimated costs, based on the information from Health insurance review agency(HIRA) and The National Health and Nutrition Examination Survey (NHANES) data, are collected.
Phase 2: Indirect cost Estimation by Sampling Survey in COPD patient Indirect cost is extra-expanses excluding hospital fees, including cost for transportation, medical instruments, home care services and loss of labor capacity reduction. The information was collected by structured questionnaire for 12 weeks.
Phase 3: Direct/Indirect cost is validated and analyzed based on the collected information from phase 1 and 2 according to severity defined by the GOLD guideline.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mild Group | FEV₁/FVC <70% and FEV₁≥80% direct/indirect cost |
| |
| Moderate Group | FEV₁/FVC <70% and 50%≤FEV₁≤80% direct/indirect cost |
| |
| Severe Group | FEV₁/FVC <70% and 30%≤FEV₁≤50% direct/indirect cost |
| |
| Very Severe Group | FEV₁/FVC <70% and FEV₁<30% direct/indirect cost |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Direct cost | Other | Money spent to treat COPD in medical institute based on HIRA |
|
| Measure | Description | Time Frame |
|---|---|---|
| Total cost of COPD | Korean won, KRW | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| The number of acute exacerbations | Number of events | 1 year |
| The cost of alternative medication use | We will add up the costs of herbal medicine, health supplement, medical equipments and respiratory rehabilitation. According to patients, the items of alternative medication use would be different. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Chronic Obstructive Pulmonary Disease (COPD)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kwang-Ha NA Yoo, Doctor | Konkuk University Hospial | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Konkuk University Hospital | Gwangjin Gu | Seoul | 05030 | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23818799 | Background | Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013 Jun 17;5:235-45. doi: 10.2147/CEOR.S34321. Print 2013. | |
| 26391471 | Background | Dang-Tan T, Ismaila A, Zhang S, Zarotsky V, Bernauer M. Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review. BMC Res Notes. 2015 Sep 21;8:464. doi: 10.1186/s13104-015-1427-y. |
| Label | URL |
|---|---|
| Health insurance review agency in south korea | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
| ID | Term |
|---|---|
| D004180 | Direct Service Costs |
| ID | Term |
|---|---|
| D017048 | Health Care Costs |
| D003365 | Costs and Cost Analysis |
| D004467 | Economics |
| D004472 | Health Care Economics and Organizations |
Not provided
Not provided
Not provided
Not provided
Not provided
| Indirect cost | Other | extra-expanses excluding hospital fees |
|
| three months |
| Cost of productivity lost | Reduction of working hour and monthly income for being late or abscence from work. | Last 7days from filling out questionnaires |
| EuroQol five dimension(EQ-5D) | Measured by questionnaire based by EQ -5D ( EQ-5D essentially consists of 2 pages - the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS) . The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems ) | 3 months |
| The total number of visits | primary clinics, emergency department and hospital admission. | 1 year |
| Nursing cost | payment for nurse (Korean won, KRW) | 1 year (past 1 year before filling questionnaires) |
| 24394800 | Background | Lokke A, Hilberg O, Tonnesen P, Ibsen R, Kjellberg J, Jennum P. Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998-2010. BMJ Open. 2014 Jan 6;4(1):e004069. doi: 10.1136/bmjopen-2013-004069. |
| 10673466 | Background | Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000 Feb;117(2 Suppl):5S-9S. doi: 10.1378/chest.117.2_suppl.5s. |
| 25675282 | Background | Mannino DM, Higuchi K, Yu TC, Zhou H, Li Y, Tian H, Suh K. Economic Burden of COPD in the Presence of Comorbidities. Chest. 2015 Jul;148(1):138-150. doi: 10.1378/chest.14-2434. |
| 21954985 | Background | Teo WS, Tan WS, Chong WF, Abisheganaden J, Lew YJ, Lim TK, Heng BH. Economic burden of chronic obstructive pulmonary disease. Respirology. 2012 Jan;17(1):120-6. doi: 10.1111/j.1440-1843.2011.02073.x. |
| 16611654 | Background | Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006 Sep;28(3):523-32. doi: 10.1183/09031936.06.00124605. Epub 2006 Apr 12. |
| 26414920 | Background | Kim J, Lee TJ, Kim S, Lee E. The economic burden of chronic obstructive pulmonary disease from 2004 to 2013. J Med Econ. 2016;19(2):103-10. doi: 10.3111/13696998.2015.1100114. Epub 2015 Oct 19. |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D003695 | Delivery of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |